Cytolytic activity and immunological responses of TKD activated natural killer cells in patients with colorectal carcinoma and non-small cell lung cancer.
Phase of Trial: Phase I
Latest Information Update: 14 Jan 2016
At a glance
- Drugs TKD-activated natural killer cells (Primary) ; Interleukin-2
- Indications Carcinoma; Colorectal cancer; Non-small cell lung cancer
- Focus Pharmacodynamics; Therapeutic Use
- 14 Jan 2016 New trial record
- 01 Jun 2004 Results published in the Internet Document
- 01 Sep 2002 Recruitment completed according to results published in the Internet Document.